Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.

1 Jan 2020

Abstract excerpt

BACKGROUND: Etoposide phosphate (VP-16) is a topoisomerase 2 (TOP2) inhibitor that demonstrated activity in patients with metastatic castration-resistant prostate cancer (mCRPC). We investigated the sensitivity of prostate cancer (PCa) cells (LNCaP, 22Rv1, PC3, DU145, PDB and MDB) to VP-16 and the possible relationship between VP-16 activity and TOP2 expression. The activity of VP-16 was compared with that of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33091733
DOI: 10.1016/j.ctarc.2020.100221

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.PMID 33091733Read ↗

Etoposide and topoisomerase II inhibition for aggressive prostate cancer: data from a translational study.Semantic proximity Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate CancerSemantic proximity Read ↗

VAV2 exists in extrachromosomal circular DNA and contributes Enzalutamide resistance of prostate cancer via stabilization of AR/ARv7Semantic proximity Read ↗

Sensitivity Profiles of Human Prostate Cancer Cell Lines to an 80 Kinase Inhibitor Panel.Semantic proximity Read ↗

Atractylenolide I ameliorated the progression of CRPC by suppressing KIF15/AR/AR-V7 signalingSemantic proximity Read ↗

Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancerSemantic proximity Read ↗

Taxane induces attenuation of the CXCR2/BCL-2 axis and sensitize prostate cancer to platinum-based treatmentsSemantic proximity Read ↗

EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive-variant prostate cancerSemantic proximity Read ↗

HF-125, a first-in-class computer-modeled novel inhibitor of Tribbles 2, for therapy of enzalutamide resistant, neuroendocrine prostate cancerSemantic proximity Read ↗

Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

Targeting RET Kinase in Neuroendocrine Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.